Back to Search Start Over

Identification of Tissue of Origin and Guided Therapeutic Applications in Cancers of Unknown Primary Using Deep Learning and RNA Sequencing (TransCUPtomics)

Authors :
Joshua J. Waterfall
Anne Vincent-Salomon
François-Clément Bidard
Alain Livartowski
Delphine Guillemot
Odette Mariani
Camille Benoist
Sylvain Baulande
Gaëlle Pierron
Christophe Le Tourneau
Sarah Watson
Julien Vibert
Olivier Delattre
Nadège Gruel
Unité de génétique et biologie des cancers (U830)
Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)
Institut Curie [Paris]
Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe
MINES ParisTech - École nationale supérieure des mines de Paris
Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)
Centre d'Investigation Clinique en Biotherapie des cancers (CIC 1428 , CBT 507 )
Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé)
Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)
Source :
The Journal of molecular diagnostics : JMD, The Journal of molecular diagnostics : JMD, 2021, 23 (10), pp.1380-1392. ⟨10.1016/j.jmoldx.2021.07.009⟩
Publication Year :
2021
Publisher :
HAL CCSD, 2021.

Abstract

International audience; Cancers of unknown primary (CUP) are metastatic cancers for which the primary tumor is not found despite thorough diagnostic investigations. Multiple molecular assays have been proposed to identify the tissue of origin (TOO) and inform clinical care; however, none has been able to combine accuracy, interpretability, and easy access for routine use. We developed a classifier tool based on the training of a variational autoencoder to predict tissue of origin based on RNA-sequencing data. We used as training data 20,918 samples corresponding to 94 different categories, including 39 cancer types and 55 normal tissues. The TransCUPtomics classifier was applied to a retrospective cohort of 37 CUP patients and 11 prospective patients. TransCUPtomics exhibited an overall accuracy of 96% on reference data for TOO prediction. The TOO could be identified in 38 (79%) of 48 CUP patients. Eight of 11 prospective CUP patients (73%) could receive first-line therapy guided by TransCUPtomics prediction, with responses observed in most patients. The variational autoencoder added further utility by enabling prediction interpretability, and diagnostic predictions could be matched to detection of gene fusions and expressed variants. TransCUPtomics confidently predicted TOO for CUP and enabled tailored treatments leading to significant clinical responses. The interpretability of our approach is a powerful addition to improve the management of CUP patients. Copyright

Details

Language :
English
ISSN :
19437811
Database :
OpenAIRE
Journal :
The Journal of molecular diagnostics : JMD, The Journal of molecular diagnostics : JMD, 2021, 23 (10), pp.1380-1392. ⟨10.1016/j.jmoldx.2021.07.009⟩
Accession number :
edsair.doi.dedup.....04d1d9c7bf93b95941ed6c068c99bacb